INTRODUCTION
Progress in defining the molecular basis of inherited diseases in man has largely been limited to the study of mutations at the globin loci. While these studies have been useful in defining the molecular pathology of the hemoglobinopathies and thalassemia syndromes, their direct relevance to other inborn errors of metabolism, especially diseases that result from defects in intracellular metabolic enzymes, has yet to be defined.
Hypoxanthine-guanine phosphoribosyltransferase (HPRT)' is a nonabundant intracellular enzyme that plays a key role in the regulation of purine metabolism in man. A partial deficiency of HPRT activity has been described in some male patients who present with hyperuricemia and an early onset of gout (1) . A virtually complete absence of this enzyme is found in patients with the Lesch-Nyhan syndrome (2) . This X-linked disease is characterized by overproduction of uric acid and a central nervous system disorder consisting of mental retardation, spasticity, choreoathetosis, and a compulsive form of self-mutilation. The extremely low levels of HPRT in human tissues has, until recently, precluded detailed studies of normal and mutant gene products.
Considerable progress in our understanding of human HPRT has occurred in the recent past. The entire amino acid sequence of HPRT purified from human erythrocytes was defined (3). In addition, a full-length cDNA for human HPRT has now been cloned and sequenced (4) . These and other studies indicate that the human erythrocyte enzyme undergoes several posttranslational modifications including (a) the removal of the NH2 terminal methionine followed by acetylation of the newly formed free NH2-terminus (3), and (b) the partial deamidation of asparagine 106 (5) . Finally, we have developed a sensitive peptide mapping procedure for studying the primary structure of human HPRT variants from limited quantities of enzyme (5) . This method has been used to identify an amino acid substitution in a variant enzyme isolated ' Abbreviations used in this paper: HPLC, high pressure liquid chromatography; HPRT, hypoxanthine-guanine phosphoribosyltransferase. (6) .
The majority of HPRT-deficient patients who present with the Lesch-Nyhan syndrome have essentially undetectable levels of HPRT enzyme. Of the 25 unrelated Lesch-Nyhan patients studied to date, only two had >5% of normal HPRT enzyme levels in erythrocytes (7-10 and unpublished results). The enzyme from one of these patients was purified to near homogeneity from erythrocytes (11) and cultured lymphoblasts (10). This mutant enzyme, which we have termed HPRTKinstOn (11) , is expressed at normal levels (7, 8) but is essentially nonfunctional in vivo due to markedly elevated Michaelis constants for both substrates (12) .
In this study we (11, 13) . Prior to subsequent analyses, the purified enzymes were denatured, and the sulfhydryls were reduced and S-pyridylethylated (3).
Cyanogen bromide and trypsin digestion. Cleavage at methionine residues was affected by incubating the intact enzymes (2-3 nmol of each) in 70% formic acid containing CNBr (150 ug) for 24 h. The reaction was terminated by dilution with 10 vol of H20, and the peptides were recovered by lyophilization. CNBr digests of the normal and mutant enzymes were subjected to isoelectric focusing in the presence of 8 M urea as described (11) . Peptides were visualized by staining with Coomassie Brilliant Blue.
The pyridylethylated enzymes (17 nmol of HPRTKinston and 27 nmol of normal HPRT) were also digested with tosylphenylchloroketone-treated trypsin (Millipore Corp., Freehold, NJ) as described (5) . Tryptic digests were fractionated by reverse-phase high pressure liquid chromatography (HPLC) using a Synchropak RP-P (0.41 X 25 cm) column (Synchrom Inc., Linden, IN). A detailed description of this peptide mapping procedure can be found elsewhere (5) . Selected tryptic peptides were sequenced to the COGHterminus by manual Edman degradation (3).
RESULTS
Enzyme purification. Normal HPRT was purified from hemolysate obtained from a single normal male subject, and from two pooled hemolysate mixtures, each containing individual units of blood from 330 different subjects. The HPRT from each of these preparations was indistinguishable in terms of subunit molecular weight (11), isoelectric points (11), and tryptic peptide map (6) . The enzyme purified from pooled normal hemolysate was focused in denaturing isoelectric focusing gels as described (11) to screen for electrophoretic heterogeneity in the normal population. There was no evidence of a more basic electrophoretic variant in this normal enzyme mixture, even when the gels were heavily overloaded with enzyme (data not shown). Based on densitometer scans of these gels, we would have been able to detect the occurrence of a basic electrophoretic variant at a frequency of 1% or greater in the normal population.
HPRTKiNStOfl was purified from erythrocytes (445 ml) of patient E.S. with an 18% recovery of enzyme activity. SDS-polyacrylamide gel electrophoresis indicated that the mutant enzyme was greater than 95% pure (11) . Amino acid analysis of a portion (6%) of the pyridylethylated form of HPRTKiNStOD documented a final quantity of 19 nmol of enzyme for further study.
CNBr peptide maps. The mutation in HPRTKinston was localized to a specific section of the enzyme by comparative analysis of the CNBr peptides. Portions of the normal and mutant enzymes were digested with CNBr and the digests were fractionated in analytical isoelectric focusing gels (Fig. 1) . The only detectable difference was in the COOH terminal CNBr peptide (CB7). This CNBr peptide, which spans amino acids 157 to 217 in the normal enzyme (3), consistently demonstrated charge heterogeneity; CB7 from normal HPRT focused at two pH values, 8.8 and 9.2. Human HPRT normally exhibits isoelectric heterogeneity due to at least two posttranslational modifications (5) . Only one of these modifications has been defined, the partial deamidation of asparagine 106 (5). The microheterogeneity in CB7 may be caused by a previously undescribed posttranslational modification of similar nature. As shown in Fig. 1 , the COOH terminal CNBr peptide species in HPRTKinStOn are both apparently shifted to higher pH values; the most basic of these peptides focused at the end of the gradient at the NaOH wick.
Comparative tryptic peptide mapping. The pyridylethylated enzymes (HPRTKimSt0n-17 nmol and normal HPRT-27 nmol) were also digested with trypsin and the digests were separated by reverse-phase HPLC.
Representative analytical separations are presented in Fig. 2 . The only apparent difference between the normal and mutant peptide maps was that peptide 24b from HPRTKimStOn consistently eluted at a slightly shorter retention time. This chromatographic abnormality was more clearly illustrated by cochromatographing equal quantities of the normal and mutant tryptic digests (Fig. 2) (2) . Recent progress in defining the structure of the normal HPRT enzyme (3) and mRNA (4) has provided a basis for a detailed molecular characterization of this poorly understood disorder. In this report, we have studied the molecular basis for HPRT-deficiency in a patient with the LeschNyhan syndrome.
HPRTKinStO, is a structural variant of human HPRT that was isolated from a patient who presented with the classic manifestations of the Lesch-Nyhan syndrome (10, 11) . A comparative tryptic-peptide analysis The intracellular concentration and intrinsic activity (Vmax) of HPRTKinston are normal (7, 8, 10, 12) .
Markedly elevated Michaelis constants (Ki) for both substrates (5-phosphoribosyl-1-pyrophosphate and the purine base) are apparently responsible for the catalytic incompetence of this enzyme in vivo (12) . The most deleterious of these effects is probably the elevated Km for 5-phosphoribosyl-1-pyrophosphate since the intracellular concentration of this substrate is 20-to 100-fold lower than the normal Km (15) . Ongoing studies of the tertiary structure and active site of normal HPRT should provide insight into the relationship between the structural alteration and functional abnormalities in HPRTKinston,
We have shown that the enzyme deficiency in this patient is due to a missence mutation in the HPRT structural gene that leads to the synthesis of a functionally abnormal enzyme. This form of Lesch-Nyhan syndrome is indeed analogous, in terms of its molecular basis, to any one of the many hemoglobinopathies that are caused by single amino acid substitutions. It is somewhat surprising, however, that so few Lesch-Nyhan patients express this kind of mutation; the predominant abnormality in most Lesch-Nyhan patients (-92%) appears to be a reduced concentration of enzyme protein rather than a defect in enzyme function (7-10 and unpublished data). The mechanisms responsible for these apparent defects in gene expression are unknown. However, the recent isolation of cDNA probes for the HPRT gene (4, 16) should greatly facilitate the molecular characterization of these mutations.
In summary, we have identified the molecular abnormality in a rare HPRT variant isolated from a patient with the Lesch-Nyhan syndrome. A single amino acid substitution, aspartic acid to asparagine at residue 193, has apparently rendered the HPRT enzyme from this patient virtually nonfunctional in vivo.
